nature portfolio

Corresponding author(s):	Frank Sobott, Stefan Howorka
Last updated by author(s):	18/05/2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

_				
Ç.	tっ	+1	ct.	ICC
٠,	ı a			11 >

n/a	Cor	nfirmed
	X	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
×		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
X		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
×		A description of all covariates tested
x		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
×		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
×		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
x		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
,		Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Masslynx 4.1 and Driftscope 2.3 (both Waters, Wilmslow, UK)

Data analysis

Yasara (http://www.yasara.org/); IMPACT, University of Oxford (https://process.innovation.ox.ac.uk/software/p/10126/impact-(academic-use-only)/1); IMOS, Indiana University—Purdue University Indianapolis (http://www.imospedia.com/); Chimera, University of California-San Francicso (https://www.cgl.ucsf.edu/chimera/)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data and models generated in this study have been deposited at https://doi.org/10.5518/1153

Hulliali lese	sarcii part	icipants			
Policy information	about <u>studies</u>	involving human research participants and Sex and Gender in Research.			
Reporting on sex and gender		n/a			
Population characteristics r		n/a			
Recruitment		n/a			
Ethics oversight		n/a			
Note that full inform	nation on the app	proval of the study protocol must also be provided in the manuscript.			
ield-spe	ecific re	eporting			
		is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences		Behavioural & social sciences			
		hall sections, see nature.com/documents/nr-reporting-summary-flat.pdf			
or a reference copy of	the document with	Tall sections, see <u>nature.com/documents/nr-reporting-summary-nat.pdf</u>			
∟ite sciei	nces st	udy design			
		e points even when the disclosure is negative.			
Sample size	Due to the ava	ailability of reagents, and to focus the study on an oligonucleotide assembly which has already been characterized with other			
Sample Size	Due to the availability of reagents, and to focus the study on an oligonucleotide assembly which has already been characterized with other methods, we did not consider extending our work to other, similar barrel-like assemblies made up of different DNA sequences. Instead we studied this particular nanostructure systematically under many different buffer conditions to ensure validity of the processes we describe.				
Data exclusions	No data were	excluded.			
Replication	to monitor qu samples were	eriments were carried out on several separate occasions with comparable results. Gels such as the ones shown here were used routinely nonitor quality of different batches of samples prepared for this work. Different nano ESI emitters and freshly prepared buffers and ples were used on different occasions, and many similar spectra were acquired during the instrument optimization process. Each extrum reported here is the result of repeated measurements over acquisition times of several minutes.			
Randomization	No systematic	randomization was done as samples are very stable and the order of measurements has no effect on the result (see above).			
Blinding	Not relevant t	o this study, analytical measurements not involving animals or patients.			
Dilliuling	Not relevant t	o this study, analytical measurements not involving animals of patients.			
Reportir	ng for s	pecific materials, systems and methods			
		s about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each materia o your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & ex	kperimental	systems Methods			
n/a Involved in t	•	n/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
Palaeontology and archaeology					
	nd other organis	— 			
Clinical da	_				
Dual use r	research of conce	ern			